Analysts Set Expectations for MNMD Q1 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Mind Medicine (MindMed) in a research report issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.38) for the quarter. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)’s Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.36) EPS and FY2029 earnings at $2.87 EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01.

Several other analysts have also commented on the company. Robert W. Baird decreased their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Evercore ISI began coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an “outperform” rating and a $23.00 target price on the stock. Chardan Capital reiterated a “buy” rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, May 9th. Finally, Cantor Fitzgerald upgraded shares of Mind Medicine (MindMed) to a “strong-buy” rating in a research report on Tuesday, May 13th. Nine investment analysts have rated the stock with a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Mind Medicine (MindMed) currently has a consensus rating of “Buy” and an average target price of $25.11.

Mind Medicine (MindMed) Stock Up 3.3%

NASDAQ MNMD opened at $7.30 on Friday. Mind Medicine has a 1-year low of $4.70 and a 1-year high of $10.44. The company has a market capitalization of $550.19 million, a price-to-earnings ratio of -3.23 and a beta of 2.52. The stock’s 50 day moving average is $6.20 and its two-hundred day moving average is $6.98. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09.

Insider Buying and Selling

In related news, insider Daniel Karlin sold 6,836 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $46,074.64. Following the transaction, the insider now owns 446,177 shares in the company, valued at $3,007,232.98. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert Barrow sold 21,208 shares of Mind Medicine (MindMed) stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the completion of the sale, the chief executive officer now owns 856,556 shares of the company’s stock, valued at approximately $5,773,187.44. The trade was a 2.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,391 shares of company stock worth $204,835 in the last three months. Insiders own 2.45% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Diadema Partners LP acquired a new stake in shares of Mind Medicine (MindMed) during the 4th quarter worth approximately $33,000. Hollencrest Capital Management boosted its stake in Mind Medicine (MindMed) by 10,833.3% in the fourth quarter. Hollencrest Capital Management now owns 7,216 shares of the company’s stock valued at $50,000 after acquiring an additional 7,150 shares during the last quarter. King Wealth Management Group bought a new position in Mind Medicine (MindMed) in the fourth quarter valued at approximately $70,000. Virtus ETF Advisers LLC bought a new position in Mind Medicine (MindMed) in the fourth quarter valued at approximately $70,000. Finally, Sharpepoint LLC acquired a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at $71,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.